CNN: The 'Wild, Wild West' of Viral Peptide Claims
Report examining viral social media claims about peptides promising DNA repair, nerve relief, and wound healing, referencing RFK Jr.'s Joe Rogan appearance supporting peptide access.
Industry News
214 stories across all digests
Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Men's Health UK: Men Injecting Peptides for Muscle and Recovery Face Real Risks
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Eli Lilly and Novo Nordisk Strike MFN Deals to Lower GLP-1 Prices
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Sherwood News: Peptide Gold Rush as Deregulation Triggers Industry Scramble
Companies are rushing to upgrade from gray-market research-grade to medical-grade peptide standards to supply doctors' offices as deregulation approaches.
Pinnacle Medicines Closes $89M Series B for AI-Driven Oral Peptide Pipeline
Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.
Hims & Hers Now Offers Novo Nordisk's FDA-Approved GLP-1 Medications
Hims & Hers announced Novo Nordisk's approved GLP-1 medications including Wegovy injections/pills and Ozempic are now available through its platform at lower-than-retail rates.
CBS News: US Peptide Searches Hit 10.1 Million in January 2026
CBS warns that viral peptide claims on social media far outpace clinical evidence, with 60% of 10.1M monthly searches related to GLP-1 drugs and many trending peptides lacking FDA approval.
Novo Nordisk to Slash US List Prices ~50% for Wegovy, Ozempic, and Rybelsus in 2027
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.
Peptide Therapeutics Market to Reach $70.2 Billion by 2031 at 7.16% CAGR
Mordor Intelligence reports the global peptide therapeutics market valued at $49.68B in 2026, projected to reach $70.2B by 2031 driven by cancer, metabolic disorders, and oral delivery advances.
1 in 8 US Adults Now Taking a GLP-1 Drug
About 1 in 8 US adults now report taking a GLP-1 drug per KFF. Experts caution effects are larger and longer-lasting when combined with lifestyle changes.
Zealand Pharma Opens U.S. Research Hub in Cambridge, MA
Zealand Pharma announced a new Cambridge research hub combining 25+ years of peptide expertise with AI-driven drug discovery, expanding its obesity and metabolic health pipeline.
WBUR/NPR: People Buying Unregulated Injectable Peptides From Chinese Factories
Investigative journalist documents how consumers buy injectable peptides from Chinese factories via social media and Reddit. The global peptide market has swelled to $50 billion annually.
PeptideSciences.com Shuts Down After FDA Enforcement Wave
PeptideSciences, one of the largest grey-market research peptide vendors in the US reportedly generating over $7 million per month, voluntarily ceased all operations on March 6. The shutdown followed coordinated enforcement from the FDA, DOJ, and FBI targeting companies selling compounds like semaglutide and tirzepatide without pharmaceutical licensing.
Medicare to Cover GLP-1 Weight Loss Drugs at $50/Month Starting July 2026
CMS confirmed that Medicare Part D beneficiaries will gain access to Wegovy and Zepbound for weight loss through the Medicare GLP-1 Bridge program starting July 2026 at a $50 monthly copayment, bridging to the full BALANCE Model launching in Medicare Part D in January 2027.
GLP-1 Drugs Reshaping American Eating: Grocery Spending Down 5.3%, Fast Food Down 8%
CNBC reports that within six months of starting a GLP-1 medication, households reduce grocery spending by 5.3% and fast-food spending by 8%. Dinner traffic has fallen 6% among regular users, with ultra-processed food spending down 10%. Food companies are racing to develop protein- and fiber-rich 'GLP-1 friendly' products.
Novo Nordisk Commits Up to $2.1 Billion to MIT Spinoff Vivtex for Oral Peptide Delivery
Novo Nordisk signed a deal worth up to $2.1 billion with Vivtex Corporation, an MIT spinoff co-founded by Bob Langer, to develop next-generation oral biologic medicines for obesity and diabetes. Vivtex's AI-driven platform screens thousands of drug delivery formulations per day with near-perfect correlation to human intestinal absorption.